Business Description
IN8bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45674E1091
Share Class Description:
INAB: Ordinary SharesDescription
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.8 | |||||
| 3-Year EPS without NRI Growth Rate | -23.4 | |||||
| 3-Year FCF Growth Rate | -29.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.93 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.36 | |||||
| 9-Day RSI | 40.72 | |||||
| 14-Day RSI | 43.55 | |||||
| 3-1 Month Momentum % | -9.76 | |||||
| 6-1 Month Momentum % | -48.3 | |||||
| 12-1 Month Momentum % | -75.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.6 | |||||
| Shareholder Yield % | -73.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -193.35 | |||||
| ROA % | -128.6 | |||||
| ROIC % | -259.19 | |||||
| 3-Year ROIIC % | -243.87 | |||||
| ROC (Joel Greenblatt) % | -337.24 | |||||
| ROCE % | -154.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.43 | |||||
| Price-to-Tangible-Book | 1.46 | |||||
| EV-to-EBIT | -0.66 | |||||
| EV-to-EBITDA | -0.72 | |||||
| EV-to-FCF | -0.82 | |||||
| Earnings Yield (Greenblatt) % | -151.52 | |||||
| FCF Yield % | -131.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IN8bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.75 | ||
| Beta | -0.04 | ||
| 3-Year Sharpe Ratio | -0.42 | ||
| 3-Year Sortino Ratio | -0.67 | ||
| Volatility % | 70.01 | ||
| 14-Day RSI | 43.55 | ||
| 14-Day ATR ($) | 0.034243 | ||
| 20-Day SMA ($) | 0.27382 | ||
| 12-1 Month Momentum % | -75.92 | ||
| 52-Week Range ($) | 0.217 - 1.74 | ||
| Shares Outstanding (Mil) | 72.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IN8bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IN8bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
IN8bio Inc Frequently Asked Questions
What is IN8bio Inc(INAB)'s stock price today?
The current price of INAB is $0.26. The 52 week high of INAB is $1.74 and 52 week low is $0.22.
When is next earnings date of IN8bio Inc(INAB)?
The next earnings date of IN8bio Inc(INAB) is 2025-03-14 Est..
Does IN8bio Inc(INAB) pay dividends? If so, how much?
IN8bio Inc(INAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers